Hematology News

FDA approved rivaroxaban in tablet form and as an oral suspension to treat and reduce the risk for recurrence of venous thromboembolism among certain populations of children.

In this video, Matthew M. Heeney, MD, spoke with Healio about presentations on gene therapeutic options for hematologic diseases from ASH Annual Meeting and Exposition.

In this video, Matthew M. Heeney, MD, highlighted “interesting” real-world and long-term follow-up studies for the treatment of sickle cell that were presented at ASH Annual Meeting and Exposition.

In this video, Matthew M. Heeney, MD, discussed results from the Solace-Kids trial, which was presented at ASH Annual Meeting and Exposition.

The FDA granted accelerated approval to voxelotor tablets for the treatment children aged 4 to 11 years with sickle cell disease.

Once-monthly fitusiran prophylaxis improved outcomes compared with on-demand treatment for patients with severe hemophilia A or B without inhibitors, according to study results presented at ASH Annual Meeting and Exposition.

Results from the CONTAIN COVID-19 trial showed that convalescent plasma did not meet prespecified efficacy endpoints in patients hospitalized with COVID-19.

A once-monthly subcutaneous prophylaxis dose of fitusiran appeared safe and effective for people with hemophilia A or B with inhibitors, according to results of a randomized phase 3 study presented at ASH Annual Meeting and Exposition.

Patients with transfusion-dependent beta-thalassemia who received betibeglogene autotemcel achieved durable transfusion independence with near-normal hemoglobin levels, according to study results with up to 7 years of follow-up.

Nearly one in six patients with hematologic disorders had a negative COVID-19 vaccination-related antibody response, according to results of a prospective, observational single-center study presented at ASH Annual Meeting and Exposition.